TMCnet News
Agios Announces Exercise of Over-Allotment Option in Public OfferingCAMBRIDGE, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that the underwriters of its previously announced public offering of common stock have fully exercised their option to purchase an additional 757,575 shares at the public offering price of $49.50 per share, resulting in additional gross proceeds of approximately $37 million. After giving effect to the full exercise of the over-allotment option, the total number of shares sold by Agios in the public offering increased to 5,808,080 shares and gross proceeds increased to approximately $287 million. The exercise of the over-allotment option is expected to close on April 28, 2017, subject to customary closing conditions. J.P. Morgan Securities LLC and Goldman, Sachs & Co. acted as joint book-running managers for the offering. Cowen and Company, LLC served as lead manager. The shares were offered by Agios pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”). A prospectus supplement relating to, and describing the terms of, the offering has been filed with the SEC and is available on the SEC’s web site at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to this offering can be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 866-803-9204; or Goldman, Sachs, & Co., Attn: Prospectus Department, 200 West Street, ew York, New York 10282, telephone: 866-471-2526, facsimile: 212-902-9316, e-mail: [email protected]. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Agios Pharmaceuticals, Inc. Cautionary Note Regarding Forward-Looking Statements CONTACTS: Kendra Adams, Senior Director, Investor & Public Relations [email protected] 617-844-6407 Renee Leck, Senior Manager, Investor & Public Relations [email protected] 617-649-8299 |